Why the study?
Diabetic cardiomyopathy is a common complication in individuals with type 2 diabetes mellitus, but its exact pathogenesis is still debated.
This review summarizes the molecular mechanisms of diabetic cardiomyopathy, including inflammation, oxidative stress, and epigenetic changes, alongside emerging targeted therapies.
DbCM mechanisms via hyperglycemia remain speculative; leaves open targeted therapies pending rigorous validation.
Diabetic cardiomyopathy (DbCM) is a common complication in individuals with type 2 diabetes mellitus (T2DM), and its exact pathogenesis is still debated. It was hypothesized that chronic hyperglycemia and insulin resistance activate critical cellular pathways that are responsible for numerous functional and anatomical perturbations in the heart. Interstitial inflammation, oxidative stress, myocardial apoptosis, mitochondria dysfunction, defective cardiac metabolism, cardiac remodeling, hypertrophy and fibrosis with consequent impaired contractility are the most common mechanisms implicated. Epigenetic changes also have an emerging role in the regulation of these crucial pathways. The aim of this review was to highlight the increasing knowledge on the molecular mechanisms of DbCM and the new therapies targeting specific pathways.
No takes yet. Share an insight, caveat, or question.
Giardinelli et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: